Kerala Ayurveda
BSE: KERALAYUR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kerala Ayurveda's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kerala Ayurveda is a vertically integrated wellness company that manages the entire value chain of Ayurvedic products, services, and education. The company operates medicinal plant cultivation, manufacturing facilities, wellness clinics, and training academies across India and the United States.
Business Model
The company generates revenue through the sale of traditional and proprietary herbal formulations via retail and e-commerce channels. Additionally, it earns income from premium wellness retreats, clinical treatment services, and global educational certification programs.
Management Commentary
Management emphasises the company's commitment to standardized clinical research and the expansion of its holistic health solutions to a global audience. The focus remains on leveraging its seven-decade legacy to integrate authentic Ayurvedic practices with modern wellness requirements.
Growth Outlook
Growth is driven by the increasing global demand for holistic health solutions and the expansion of the company's international footprint, particularly in the United States. Further growth is supported by the scaling of its educational wing and the digitisation of its product distribution network.
Key Risks
- Regulatory Compliance. The company faces stringent and evolving regulatory requirements for herbal products and clinical services in both domestic and international markets.
- Supply Chain Volatility. As a vertically integrated firm, the company is susceptible to risks associated with the cultivation and sourcing of medicinal plants, which can be impacted by climate and agricultural factors.
- Market Competition. The wellness and alternative medicine sector is highly fragmented, with increasing competition from both traditional practitioners and modern FMCG entrants.
- Geopolitical and Currency Risk. Operating across international borders, particularly in the United States, exposes the company to foreign exchange fluctuations and varying healthcare policies.
Start your research today
Unlock AI insights, financials, peers and live data on Kerala Ayurveda and 5,000+ companies — free.
Key Metrics
REVENUE
₹131 Cr
TTM · consolidated
NET PROFIT
₹20 Cr
TTM · consolidated
EPS
₹18.67
TTM · consolidated
RETURN ON EQUITY
205.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
72.7%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
8.6x
Q4 FY26 · consolidated
EBITDA MARGIN
26.5%
TTM · consolidated
NET PROFIT MARGIN
21.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
7.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kerala AyurvedaKERALAYUR | ₹232 Cr | 9.56 | 8.82 | 6.7% | 26.5% | 205.9% | 72.7% | -62.6% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Kerala Ayurveda
BSE: KERALAYUR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kerala Ayurveda's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kerala Ayurveda is a vertically integrated wellness company that manages the entire value chain of Ayurvedic products, services, and education. The company operates medicinal plant cultivation, manufacturing facilities, wellness clinics, and training academies across India and the United States.
Business Model
The company generates revenue through the sale of traditional and proprietary herbal formulations via retail and e-commerce channels. Additionally, it earns income from premium wellness retreats, clinical treatment services, and global educational certification programs.
Management Commentary
Management emphasises the company's commitment to standardized clinical research and the expansion of its holistic health solutions to a global audience. The focus remains on leveraging its seven-decade legacy to integrate authentic Ayurvedic practices with modern wellness requirements.
Growth Outlook
Growth is driven by the increasing global demand for holistic health solutions and the expansion of the company's international footprint, particularly in the United States. Further growth is supported by the scaling of its educational wing and the digitisation of its product distribution network.
Key Risks
- Regulatory Compliance. The company faces stringent and evolving regulatory requirements for herbal products and clinical services in both domestic and international markets.
- Supply Chain Volatility. As a vertically integrated firm, the company is susceptible to risks associated with the cultivation and sourcing of medicinal plants, which can be impacted by climate and agricultural factors.
- Market Competition. The wellness and alternative medicine sector is highly fragmented, with increasing competition from both traditional practitioners and modern FMCG entrants.
- Geopolitical and Currency Risk. Operating across international borders, particularly in the United States, exposes the company to foreign exchange fluctuations and varying healthcare policies.
Start your research today
Unlock AI insights, financials, peers and live data on Kerala Ayurveda and 5,000+ companies — free.
Key Metrics
REVENUE
₹131 Cr
TTM · consolidated
NET PROFIT
₹20 Cr
TTM · consolidated
EPS
₹18.67
TTM · consolidated
RETURN ON EQUITY
205.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
72.7%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
8.6x
Q4 FY26 · consolidated
EBITDA MARGIN
26.5%
TTM · consolidated
NET PROFIT MARGIN
21.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
7.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26